echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first STING agonist approved for clinical use

    The first STING agonist approved for clinical use

    • Last Update: 2021-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 16, Chengdu Pilot issued an announcement that the company's clinical trial application for the company's innovative drug HG381 for injection has obtained the default approval of the State Food and Drug Administration, and plans to conduct clinical research on the treatment of advanced solid tumors.


    The human body's innate immune system recognizes molecules in pathogenic microorganisms through pattern recognition receptors (PRR) and triggers an immune activation response.


    HG381 is a new molecular entity independently developed by Chengdu Lead based on DNA-encoded compound library technology and small molecule new drug research and development platform.


    At present, several innovative drugs based on this mechanism are in the early stage of clinical trials in the world.


    Source: Chengdu Pilot's official website

    Novartis’ ADU-S100 obtained from Aduro and Merck’s MK-1454 are both small molecule cyclic dinucleotide (cGAMP) natural ligand derivatives.


    Among domestic companies, the STING agonist IMSA101 developed by Jiahe Biological has already carried out Phase I clinical trials abroad.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.